Prognostic impact of circulating interleukin 6 levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A subgroup analysis from the AUTENTIC study
Por:
Kareaga, MM, Paul, AM, Echebarria, ID, Arrula, VA, Sanchez, LT, Brun, LP, Davila, L, Etxebarria, II, Ibarbia, MA, Mediavilla, JG, Ruiz, IM, Garcia, IG and Bujanda, IL
Publicada:
1 nov 2025
Ahead of Print:
1 nov 2025
Resumen:
Filiaciones:
Kareaga, MM:
HUA Hosp Univ Araba Txagorritxu, Med Oncol Dept, Vitoria, Spain
Paul, AM:
Hosp Galdakao Usansolo, Med Oncol Dept, Galdakao, Spain
Echebarria, ID:
Hosp Univ Donostia, Dept Oncol, San Sebastian, Spain
Arrula, VA:
Royal Navarre Hosp, Med Oncol, Complejo Hosp Navarra, Pamplona, Spain
Sanchez, LT:
Royal Navarre Hosp, Med Oncol, Complejo Hosp Navarra, Pamplona, Spain
:
Hosp Mataro Consorcio Sanitario Maresme, Med Oncol, Mataro, Spain
Davila, L:
Hosp Univ San Pedro, Med Oncol, Logrono, Spain
Etxebarria, II:
HUA Hosp Univ Araba Txagorritxu, Med Oncol, Vitoria, Spain
Ibarbia, MA:
Hosp Galdakao Usansolo, Med Oncol, Galdakao, Spain
Mediavilla, JG:
Onkologiko Donostia Kutxa Fundaz, Med Oncol, San Sebastian, Spain
Ruiz, IM:
Royal Navarre Hosp, Oncol Dept, Complejo Hosp Navarra, Pamplona, Spain
Garcia, IG:
HUA Hosp Univ Araba Txagorritxu, Med Oncol, Vitoria, Spain
Bujanda, IL:
Royal Navarre Hosp, Internal Med, Complejo Hosp Navarra, Pamplona, Spain
|